As biopharma advances, the question arises: how to pay for the new cures and treatments that are becoming more readily available to patients? In October 2018, In Vivo convened a panel of market experts and investment analysts to discuss the challenges facing biopharma innovators regarding market access. Tap in to their unique insights into issues such as dealing with payment models (like integrated delivery networks), fostering more direct connectivity between the C-suite and market access, and the increasing institutionalization of value-based drug evaluation frameworks.
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2022
- 550 Pages